CSD/BSE&NSE/PR/2026-2027
June 16, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development"**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Kandari Sangeetha Laxmi
Digitally signed by Kandari Sangeetha Laxmi
Date: 2026.06.16 09:20:14 +05'30'

K. Sangeetha Laxmi
Company Secretary

Encl.: as above

News Release

Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development.

**Favorable safety profile with no dose-limiting toxicities.*
**Achieved projected therapeutic exposures in plasma and at the target site.*
**Robust pharmacodynamic activity demonstrating evidence of CNS activity.*
**PK assessments showed no clinically meaningful differences between male and female.*
**Food intake had no clinically relevant impact on the PK of SUVN-I6107.*
**Pharmacodynamic Biomarker assessments demonstrated evidence of increased alertness and enhanced information processing.*

Hyderabad, India, 16-June-2026. - Suven Life Sciences Limited a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, today announced the successful completion of Phase-1 first-in-human (FIH) clinical study of SUVN-I6107, a novel, potent, and highly selective muscarinic M1 positive allosteric modulator (M1-PAM). The study demonstrated favorable safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, supporting the advancement of SUVN-I6107 into Phase-2 clinical development.

Phase-1 Study Overview: The completed FIH Phase-1 study (NCT06705088) was a two-part, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SUVN-I6107 in healthy human volunteers. The Single Ascending Dose (SAD) segment enrolled 40 participants across five cohorts and included assessments of food effects and potential sex-related differences in PK. The Multiple Ascending Dose (MAD) segment enrolled 24 participants across three cohorts, with participants receiving SUVN-I6107 or placebo daily for 14 consecutive days. The study also incorporated translational biomarkers to assess CNS activity, providing evidence of the compound's pharmacological effects on brain function and supporting its mechanism of action.

Phase-1 Study Findings: SUVN-I6107 demonstrated a favorable safety and tolerability profile across all dose levels evaluated in the study. No predefined dose-escalation stopping criteria were met, and no treatment related adverse event led to study drug discontinuation or participant withdrawal. Importantly, no serious adverse events (SAEs) or deaths were reported. All treatment-emergent adverse events observed during the study were mild to moderate in severity and resolved prior to study completion.

SUVN-I6107 demonstrated predictable, dose-proportional pharmacokinetics, with exposure (C_{max} and AUC) increasing with increase in dose. The compound exhibited a median time to peak plasma concentration (T_{max}) of approximately 2–6 hours and a mean elimination half-life ($t_{½}$) of approximately 7 to 11 hours across the evaluated dose range. Importantly, PK exposures associated with projected therapeutic efficacy were achieved. PK assessments showed no clinically meaningful differences between male and female participants, indicating that dose adjustment based on gender is unlikely to be necessary. Food intake also had no clinically relevant impact on the PK of SUVN-I6107, supporting a flexible dosing regimen that can be administered irrespective of meals in future studies.

Pharmacodynamic biomarker assessments demonstrated evidence of increased alertness and enhanced information processing, supporting the central pharmacological activity of SUVN-I6107 and its effects on brain function.

"*The completion of the Phase-1 study for SUVN-I6107 represents an important development milestone for the M1-PAM program and further expands our clinical-stage pipeline in neuroscience. As the fifth internally discovered candidate (NCE) to enter clinical development, SUVN-I6107 reflects the productivity of our research organization and our continued focus on advancing differentiated CNS therapies. We look forward to progressing the program into Phase-2 clinical studies and further evaluating its potential in areas of significant unmet medical needs,"* said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

"The successful completion of this first-in-human study marks an important milestone in the clinical development of SUVN-I6107. The study incorporated translational biomarkers, alongside comprehensive evaluations of safety, tolerability, pharmacokinetics, and pharmacodynamics. The data generated provided the evidence of CNS activity, support the advancement of SUVN-I6107 into Phase-2 clinical evaluation, and will help guide future development plans," said Mr. Ramakrishna Nirogi, President and Chief Scientific Officer of Suven Life Sciences.

Detailed findings will be presented in future medical conference and/or peer-reviewed journal publications.

About SUVN-I6107: SUVN-I6107 is a novel, potent, and selective muscarinic M1 positive allosteric modulator (M1-PAM) with minimal intrinsic agonist activity. It exhibits no significant affinity for muscarinic subtypes M2 to M5. SUVN-I6107 demonstrates excellent pharmacokinetic properties and good brain penetration, achieving high cerebrospinal fluid concentrations in rats. It has shown robust efficacy in animal models of cognition. Additionally, it has a wide margin of safety based on 28-day toxicity studies and anticipated efficacy. Suven Life Sciences owns the intellectual property rights for SUVN-I6107 in all major markets.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS ongoing); Ropanicant (SUVN-911) for MDD (Open-label Phase 2a study completed; Double blind randomized Placebo controlled Phase-2b study recruitment completed); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study completed). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*